RCS
BIIB icon

R2 Capital Strategies’s Biogen BIIB Stock Holding History

R2 Capital Strategies’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
+1,030
New +$197K 0.1% 113

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

R2 Capital Strategies's BIIB Position: Q2 2026 in Review

R2 Capital Strategies opened a new position in Biogen (BIIB) in Q2 2026: 1,030 shares worth $223K. The stake represents 0.1% of the portfolio and ranks #113 among its holdings.

981 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • R2 Capital Strategies held 1,030 shares of Biogen worth $223K as of Q2 2026.
  • Biogen was a new R2 Capital Strategies position in Q2 2026.
  • Biogen made up 0.1% of R2 Capital Strategies's portfolio in Q2 2026, its #113 holding.
  • 981 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on R2 Capital Strategies's 13F filing for Q2 2026, filed 23 Jul 2026.